Literature DB >> 15660476

Changes in the costs of treating mental health disorders: an overview of recent research findings.

Ernst R Berndt1.   

Abstract

This article reviews recent evidence on changes over time in the direct medical costs of treating three of the more common mental health disorders in the US: the acute (16-week) phase of major depressive disorder, the ongoing treatment of schizophrenia, and the ongoing treatment of bipolar I disorders. The three studies discussed in this article cover various time intervals over the decade from 1991 through 2000, and encompass both private sector and governmental funding sources. Although there has been a shift over time away from intensive psychosocial/psychotherapy and towards increasingly expensive psychopharmacotherapy for all three disorders, total direct medical costs of treatment for each of these three mental health disorders have been declining over time. However, a substantial portion of treatment is not supported by clinical evidence.

Entities:  

Mesh:

Year:  2004        PMID: 15660476     DOI: 10.2165/00019053-200422002-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  11 in total

1.  The controversy of increased spending for antidepressants.

Authors:  T W Croghan
Journal:  Health Aff (Millwood)       Date:  2001 Mar-Apr       Impact factor: 6.301

2.  Practice guideline for the treatment of patients with bipolar disorder (revision).

Authors: 
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

3.  The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes.

Authors:  Ernst R Berndt; Anupa Bir; Susan H Busch; Richard G Frank; Sharon-Lise T Normand
Journal:  J Health Econ       Date:  2002-05       Impact factor: 3.883

4.  Public opinion and the mental health parity debate: lessons from the survey literature.

Authors:  K W Hanson
Journal:  Psychiatr Serv       Date:  1998-08       Impact factor: 3.084

5.  Spending for mental health and substance abuse treatment, 1996.

Authors:  D McKusick; T L Mark; E King; R Harwood; J A Buck; J Dilonardo; J S Genuardi
Journal:  Health Aff (Millwood)       Date:  1998 Sep-Oct       Impact factor: 6.301

6.  Quality of care in mental health: the case of schizophrenia.

Authors:  A F Lehman
Journal:  Health Aff (Millwood)       Date:  1999 Sep-Oct       Impact factor: 6.301

7.  Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey.

Authors:  A F Lehman; D M Steinwachs
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

8.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

Authors:  A F Lehman; D M Steinwachs
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

9.  QUALITY-CONSTANT "PRICES" FOR THE ONGOING TREATMENT OF SCHIZOPHRENIA: AN EXPLORATORY STUDY*

Authors:  Richard G Frank; Ernst R Berndt; Alisa B Busch; Anthony F Lehman
Journal:  Q Rev Econ Finance       Date:  2004-07

10.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Authors:  R C Kessler; K A McGonagle; S Zhao; C B Nelson; M Hughes; S Eshleman; H U Wittchen; K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1994-01
View more
  2 in total

1.  Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care.

Authors:  Timothy B Baker; Richard M McFall; Varda Shoham
Journal:  Psychol Sci Public Interest       Date:  2008-11-01

2.  Impairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey Replication.

Authors:  B G Druss; I Hwang; M Petukhova; N A Sampson; P S Wang; R C Kessler
Journal:  Mol Psychiatry       Date:  2008-02-19       Impact factor: 15.992

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.